Technical Analysis for ONC - Oncolytics Biotech Inc.

Grade Last Price % Change Price Change
D 3.37 -2.32% -0.080
ONC closed down 2.32 percent on Monday, May 10, 2021, on 66 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical ONC trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction -2.32%
BB Squeeze + Lower Band Touch Range Contraction -2.32%
Older End-of-Day Signals for ONC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 18 hours ago
Down 3% about 18 hours ago
Down 2% about 18 hours ago
Down 1% about 18 hours ago
Down 5% 4 days ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Oncolytics Biotech Inc. Description

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.


Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Clinic Cancer RTT Therapy Clinical Trial Oncology Blastoma Chemotherapy Lung Cancer Non Small Cell Lung Cancer Glioblastoma

Is ONC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.06
52 Week Low 2.0
Average Volume 249,546
200-Day Moving Average 3.266
50-Day Moving Average 4.062
20-Day Moving Average 3.713
10-Day Moving Average 3.655
Average True Range 0.262
ADX 18.03
+DI 15.160
-DI 28.061
Chandelier Exit (Long, 3 ATRs ) 5.133
Chandelier Exit (Short, 3 ATRs ) 4.127
Upper Bollinger Band 3.971
Lower Bollinger Band 3.454
Percent B (%b) -0.16
BandWidth 13.910
MACD Line -0.192
MACD Signal Line -0.160
MACD Histogram -0.0317
Fundamentals Value
Market Cap 145.92 Million
Num Shares 43.3 Million
EPS -1.02
Price-to-Earnings (P/E) Ratio -3.32
Price-to-Sales 0.00
Price-to-Book 7.41
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.565
Resistance 3 (R3) 3.577 3.523 3.533
Resistance 2 (R2) 3.523 3.474 3.518 3.522
Resistance 1 (R1) 3.447 3.443 3.420 3.435 3.511
Pivot Point 3.393 3.393 3.380 3.388 3.393
Support 1 (S1) 3.317 3.344 3.290 3.305 3.229
Support 2 (S2) 3.263 3.313 3.258 3.218
Support 3 (S3) 3.187 3.263 3.208
Support 4 (S4) 3.175